---
run_id: halo-evidence-vs-diagnosis-validation-v11-vanilla-04
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: vanilla
run_number: 4
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 401
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
condition_packet_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
output_file: model-outputs/vanilla-04.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 04)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `vanilla`, run 4 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 401, on the frozen condition packet.

## Output

I recommend the **Claim File Review**.

### The Recommendation
You should advise the CEO to commit to the Claim File Review. While the executive team is celebrating a "commercially disciplined" quarter, your data suggests you are currently experiencing a **false positive**.

The revenue growth is driven by pricing incentives (the bundle), not value realization. The usage spike is "phantom usage" (managers auditing old files rather than adjusters processing live ones). Most critically, the "lack of wrong recommendation" tickets is a reporting artifact—users have simply stopped reporting bugs because they've stopped trusting the tool and moved their complaints to training channels.

The Claim File Review is the only option that penetrates this "entanglement." By auditing actual files, you move from *proxy metrics* (clicks and bundles) to *outcome metrics* (acceptance vs. override). This will tell you if SignalPath is actually solving a problem or if it is simply a "roadmap promise" that Sales is using to pull renewals forward.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and qualitative. Unlike the Usage Quality Sprint or the Commercial Cleanroom, it does not provide a statistically significant "dashboard" for the board. It risks delivering "anecdotal" evidence at a moment when the executive team is riding a high of quantitative growth (16% expansion). There is a significant risk that the CEO will view this as "over-analyzing" a winning streak and prefer the speed of the Usage Quality Sprint or the aggressive validation of the Commercial Cleanroom.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" hurdle in health-liability is a systemic regulatory requirement (e.g., a legal mandate for specific documentation) rather than a product usability issue.

If the failure is regulatory/legal, no amount of "usage quality" or "file review" will fix the product—the value proposition itself is broken for that segment. In that case, you must immediately stop the "roadmap pitch" (the Cleanroom) to prevent a massive churn event next year when those regional carriers and health-liability accounts realize the tool cannot legally be used in their workflow.
